Pfizer Inc. (PFE)
Pfizer Stock: A Golden Buying Opportunity (Rating Upgrade)
I upgrade Pfizer to "Strong Buy" due to its undervaluation, strong pipeline, and operational growth despite recent stock price declines. Pfizer's Q3 FY2024 earnings showed significant revenue and EPS growth, driven by COVID-19 therapies and oncology products, indicating robust strategic execution. The company's diversified portfolio, including successful vaccines and promising new drugs, positions it for long-term success and potential stock price re-rating.
PFE or NVO: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer: Too Cheap To Ignore
Pfizer's fundamentals are improving, with solid Q3 earnings, upgraded 2024 guidance, and a strategic pivot towards the fast-growing oncology market. The stock is undervalued with a 32% upside potential based on a $33.39 intrinsic value per share, using the dividend discount model. Despite recent share price weakness, Pfizer offers a compelling forward dividend yield, supported by strong revenue growth and aggressive R&D spending.
Pfizer Stock Falls 8% in a Month: Should You Buy the Dip?
Investors with a long-term horizon may consider buying PFE stock at its present attractive valuation.
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Things aren't getting much better for Pfizer (PFE -1.29%). The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it has produced during the past two years.
What's Happening With PFE Stock?
Pfizer stock (NYSE: PFE) is down 7% in a month, amid rising concerns over the future of vaccines under Robert F. Kennedy Jr. in the new government, given the perception of him being a prominent anti-vaccine activist.
Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments
Goldman Sachs hosted a meeting with Pfizer Inc's PFE newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025).
Is This a New Reason to Buy Pfizer Stock Hand Over Fist?
Despite Pfizer's (PFE 0.23%) recent struggles with falling earnings and a bid by an activist investor to unseat its leadership, the pharma juggernaut is still actively advancing its core priorities and giving investors plenty of reasons to consider buying its stock while it's cheap.
Are Investors Undervaluing Pfizer (PFE) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
Leading vaccine makers like Eli Lilly and Co. NYSE: LLY, Pfizer Inc. NYSE: PFE, and AstraZeneca plc NASDAQ: AZN may have faded from the spotlight since the peak of the COVID-19 pandemic, but now there is reason to expect renewed interest. As investors look ahead to the second Trump administration, the incoming president's nomination of outspoken vaccine critic Robert F.
Is Pfizer Stock in Trouble?
One stock that just can't seem to catch a break of late is Pfizer (PFE 0.23%). Even though it posted some decent earnings numbers, investors can't shake the fear that the business is facing daunting headwinds that could send its $145 billion valuation lower in the months and years ahead.
